Your Source for Venture Capital and Private Equity Financings

Delphia Therapeutics Scores $67 Series A

CAMBRIDGE, MA, Delphia Therapeutics announced its launch and $67 million Series A financing.
Delphia Therapeutics, Inc. (Delphia), announced its launch to pioneer a new area of cancer biology - activation lethality - which targets cancer's surprising vulnerability to oncogene overactivation Delphia completed a $67 million Series A financing led by premier early life sciences investors including GV (Google Ventures), Nextech Invest, Polaris Innovation Fund and Alexandria Venture Investments.
(c) by Massinvestor, Inc. For contact info, please check out our about page.
>> Click here for in-depth research on 9,000+ startups and 5,000+ VC investors